10月28日——美国卫生部门将暂时允许药房和医生使用一系列肽类成分配制药物，同时监管机构将决定这些物质是否应正式获准用于配制药品。
Oct 28 - The US health department will temporarily allow pharmacies and physicians to compound drugs using a range of peptide ingredients, while regulators decide whether the substances should be formally permitted for use in compounded medicines.
获准生产的肽类属于美国食品药品监督管理局（FDA）顾问小组建议放宽限制的肽类之一。
The peptides that are allowed to be manufactured are among the ones that an FDA advisory panel recommended be subject to fewer restrictions.
该小组在七月投票决定对七种审查中的肽类中的六种放宽配制限制，其中包括广受欢迎的组织修复化合物BPC-157。
The panel had in July voted to loosen compounding restrictions on six out of seven peptides under review, including the popular tissue-repair compound BPC-157.
肽类，即短链氨基酸，在过去一年因健康类网红的背书而人气激增，应用范围涵盖抗衰老、肌肉恢复和组织修复等。
Peptides, or short chains of amino acids, have boomed in popularity over the past year, driven by endorsements from wellness influencers, for uses ranging from anti-aging to muscle recovery and tissue repair.